transplant drugs

Question 1

ATGAM/ALG/OKT3 class

Answer 1

pan-t cell antibody

Question 2

ATGAM/ALG/OKT3 mechanism

Answer 2

causes t cell reduction through ADCC and removal through opsinization in the spleen.

Question 3

ATGAM/ALG/OKT3 therapeutics

Answer 3

induction immune suppression for the transplant of tissues

Question 4

ATGAM/ALG/OKT3 se

Answer 4

Serum sickness reaction characterized by fevers, chills, tachycardia, hypertension or hypotension, myalgias, and rash. there is also the sensitivity to infections

Question 5

decliuzimab class

Answer 5

IL-2 receptor antibody

Question 6

decliuzimab mechanism

Answer 6

inhibits the IL-2 dependent proliferation of t cells.

Question 7

decliuzimab therapeutics

Answer 7

induction of immune suppression for transplant.

Question 8

basiliximab class

Answer 8

IL-2 receptor antibody

Question 9

basiliximab mechanism

Answer 9

reduces the IL-2 dependent t cell proliferation

Question 10

basiliximab therapeutics

Answer 10

transplant induction

Question 11

alemtuzimab class

Answer 11

CD52 antibody

Question 12

alemtuzimab mechanim

Answer 12

suppresses both b and t cells for a profound lymphopenia.

Question 13

alemtuzimab therapeutics

Answer 13

immune suppression induction for transplant.

Question 14

methylpredinisolone class

Answer 14

glucocorticoid

Question 15

methylpredinisolone mechanims

Answer 15

non specific antiinflammatory agent

Question 16

methylpredinisolone therapeutics f

Answer 16

induction of immune suppression

Question 17

methylpredinisolone SE

Answer 17

Diabetes mellitus, hyperlipidemia, hypertension, fluid retention, myopathy, osteoporosis, and a predisposition toward opportunistic infections

Question 18

cyclosporin class

Answer 18

calcineurin inhibitor

Question 19

cyclosporin mechanism

Answer 19

blocks Il-2 production

Question 20

cyclosporin therapeutics

Answer 20

maintenance of immune suppression

Question 21

cyclosporin SE

Answer 21

Renal insufficiency, hypertension, dyslipidemia, metabolic derangements. there are significant drug interactions with anything metabolized by CYP3A4

Question 22

tacrolimus class

Answer 22

calcineurin inhibitor (this is correct)

Question 23

tacrolimus mechanism

Answer 23

IL-2 production inhibitor

Question 24

tacrolimus therapeutics

Answer 24

maintenance of immune suppression

Question 25

tacrolimus SE

Answer 25

Renal insufficiency, hypertension, dyslipidemia, metabolic derangements, New onset DM; hemolytic-uremic syndrome, Significant drug interactions with any drug metabolized by CYP3A4

Question 26

azothiaprime class

Answer 26

antimetabolite.

Question 27

azothiaprime mechanism

Answer 27

inihibits de novo synthesis of purines.

Question 28

azothiaprime therapeutics

Answer 28

maintenance of immune suppression

Question 29

azothiaprime SE

Answer 29

Leukopenia; hepatotoxicity; pancreatic toxicity

Question 30

mycophenylate class

Answer 30

antimetabolite

Question 31

mycophenylate mechanism

Answer 31

inhibits de novo syn of purines

Question 32

mycophenylate therapeutics

Answer 32

maintenance of immune suppression

Question 33

mycophenylate SE

Answer 33

Leukopenia (less than azathioprine; GI toxicity

Question 34

sirolimus class

Answer 34

mtor inhibition

Question 35

sirolimus mechanism

Answer 35

inhibits the progression of cell cycle from g1 to s phase.

Question 36

sirolimus therapeutic

Answer 36

maintenance of immune suppression

Question 37

sirolimus SE

Answer 37

Hyperlipidemia, oral ulcerations, impaired wound healing, interstitial pneumonitis

Question 38

balatacept

Answer 38

antibody that blocks costimulation of t cells used in the maintenance of immunosuppression

Question 39

rituximab class

Answer 39

cd 20 inhibitor that causes b cell destruction